Bayer oncology vet Robert LaCaze has his eyes on next steps — landing his first gig as CEO of Sadelain co-founded biotech
Three weeks after Bayer put out word that Robert LaCaze, its head of their oncology strategic business unit, was jumping ship, we now know where he’s headed: the transatlantic T-cell biotech Mnemo Therapeutics, where LaCaze will be taking up the helm and moving forward as CEO on May 1.
Founding CEO Alain Maiore is staying with the company, but is pivoting his role from CEO to COO.
Michel Sadelain, the CAR-T researcher and Juno co-founder at Memorial Sloan Kettering, had put his name and cell engineering technology behind the startup when it officially launched back in June — and he’s listed as a scientific co-founder. Maiore said at the time that they as a company were ready to bring on the next generation of cell therapies in whatever flavor they come.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters